Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.72 |
| ▸ | MET | P08581 | 6/20 | 0.51 |
| ▸ | ATR | Q13535 | 1/20 | 0.49 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.49 |
| ▸ | CSF1R | P07333 | 2/20 | 0.48 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.47 |
| ▸ | IKBKB | O14920 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13404647 | 1.00 | HRH3 (0.72) | HRH3METATRALKCSF1R | |
| SCHEMBL3206536 | 0.85 | HRH3 (0.52) | HRH3METCSF1R | |
| SCHEMBL3206524 | 0.85 | HRH3 (0.52) | HRH3METCSF1R | |
| SCHEMBL3196699 | 0.84 | HRH3 (0.57) | HRH3METATRALKCSF1R | |
| SCHEMBL3196709 | 0.84 | HRH3 (0.57) | HRH3METATRALKCSF1R | |
| SCHEMBL5220693 | 0.84 | HRH3 (1.00) | HRH3 | |
| SCHEMBL2340660 | 0.82 | MET (0.61) | HRH3METATRALK | |
| SCHEMBL12393031 | 0.82 | MET (0.61) | HRH3METATRALK | |
| SCHEMBL2344330 | 0.81 | HRH3 (0.65) | HRH3METATRALK | |
| SCHEMBL2344325 | 0.81 | HRH3 (0.65) | HRH3METATRALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1784400-B1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | LILLY CO ELI (US) | 2015-01-14 | — | — | EP | disclosed |
| US-7705025-B2 | Histamine H3 receptor agents, preparation and therapeutic uses | ELI LILLY AND COMPANY (US) | 2010-04-27 | — | — | US | disclosed |
| US-7705025-B2 | Histamine H3 receptor agents, preparation and therapeutic uses | ELI LILLY AND COMPANY (US) | 2010-04-27 | — | — | US | disclosed |
| US-20100029608-A1 | Histamine H3 Receptor Agents, Preparation and Therapeutic Uses | FINLEY DON RICHARD | 2010-02-04 | — | — | US | disclosed |
| US-20100029608-A1 | Histamine H3 Receptor Agents, Preparation and Therapeutic Uses | FINLEY DON RICHARD | 2010-02-04 | — | — | US | disclosed |
| US-20090048225-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY | 2009-02-19 | — | — | US | disclosed |
| US-20090048225-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048225-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | HRH3, HRH4, HCRTR1 | HRH3 1/4885MET 787/4885ATR 3716/4885 |
| US-20100029608-A1 | Histamine H3 Receptor Agents, Preparation and Therapeutic Uses | HRH3, HRH4, HCRTR1 | HRH3 1/4885MET 766/4885ATR 3711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.